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Abstract	  
Community-­‐acquired	  pneumonia	  (CAP)	  in	  sub	  Saharan	  Africa	  is	  a	  common	  cause	  of	  adult	  
hospitalisation	  and	  is	  associated	  with	  significant	  mortality.	  HIV	  prevalence	  in	  the	  region	  leads	  to	  
differences	  in	  CAP	  epidemiology	  compared	  with	  most	  high-­‐income	  settings:	  patients	  are	  younger,	  and	  
co-­‐infection	  with	  tuberculosis	  and	  opportunistic	  infections	  is	  common	  and	  difficult	  to	  diagnose.	  
Resource	  limitations	  affect	  the	  availability	  of	  medical	  expertise,	  radiological	  and	  laboratory	  diagnostic	  
services.	  These	  factors	  impact	  on	  key	  aspects	  of	  healthcare,	  including	  pathways	  of	  investigation,	  
severity	  assessment	  and	  the	  selection	  of	  empirical	  antimicrobial	  therapy.	  This	  review	  summarises	  
recent	  data	  from	  sub-­‐Saharan	  Africa	  describing	  the	  burden,	  aetiology,	  risk	  factors	  and	  outcome	  of	  
CAP.	  We	  describe	  the	  rational	  and	  context-­‐appropriate	  approach	  to	  CAP	  diagnosis	  and	  management,	  
including	  supportive	  therapy.	  Priorities	  for	  future	  research	  to	  inform	  strategies	  for	  CAP	  prevention	  
and	  initial	  management	  are	  suggested.	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Introduction	  
Community-­‐acquired	  pneumonia	  (CAP)	  is	  a	  common	  cause	  of	  morbidity	  and	  mortality	  in	  adults	  
worldwide.	  Whilst	  the	  context	  of	  disease	  is	  different	  in	  high	  and	  low	  income	  countries,	  common	  
questions	  arise,	  relating	  to	  prevention,	  antimicrobial	  choice,	  risk	  stratification	  and	  supportive	  therapy.	  
In	  sub-­‐Saharan	  Africa,	  key	  differences	  in	  clinical	  management	  include	  HIV-­‐related	  co-­‐infections	  
(particularly	  tuberculosis),	  and	  limited	  resources	  with	  respect	  to	  healthcare	  workers,	  drugs	  and	  
equipment.	  This	  review	  summarises	  recent	  data	  on	  the	  pneumonia	  burden,	  aetiology,	  risk	  factors	  and	  




Globally,	  pneumonia	  is	  the	  commonest	  infectious	  cause	  of	  death,	  the	  fourth	  commonest	  cause	  of	  
death	  overall	  and	  the	  second	  leading	  cause	  of	  life	  years	  lost.1,2	  In	  2010,	  lower	  respiratory	  tract	  
infection	  (LRTI)	  accounted	  for	  2.8	  million	  deaths	  and	  the	  loss	  of	  115	  million	  disability-­‐adjusted	  life	  
years.2,3	  In	  sub-­‐Saharan	  Africa,	  estimates	  suggest	  4	  million	  episodes	  of	  pneumonia	  each	  year,	  resulting	  
in	  200,000	  deaths.4	  Respiratory	  illness	  and	  infectious	  diseases	  are	  the	  commonest	  reason	  for	  adult	  
hospitalisation	  in	  many	  countries	  in	  the	  region.5,6	  The	  annual	  incidence	  of	  LRTI	  in	  adults	  under	  60	  
years	  is	  estimated	  at	  10	  episodes	  per	  1000,	  but	  is	  several-­‐fold	  higher	  in	  the	  elderly	  and	  in	  HIV	  infected	  
individuals.1	  	  
Risk	  factors	  
In	  high	  income	  settings	  the	  dominant	  risk	  factors	  for	  CAP	  are:	  increasing	  age;7,8	  male	  sex;8,9	  comorbid	  
illness,	  particularly	  COPD,	  congestive	  heart	  failure,	  cerebrovascular	  disease,	  dementia	  and	  diabetes;10-­‐
15	  and	  smoking.16	  These	  physiological	  and	  comorbid	  risks	  factors	  are	  likely	  to	  have	  similar	  associations	  
with	  CAP	  in	  sub-­‐Saharan	  Africa,	  but	  these	  risks	  are	  dwarfed	  by	  that	  associated	  with	  HIV	  infection:	  
before	  antiretroviral	  therapy	  (ART),	  a	  17	  to	  35	  fold	  increase	  in	  disease17,18	  and	  100	  fold	  increase	  in	  
pneumococcal	  bacteraemia	  compared	  with	  control	  populations.19	  Even	  on	  established	  ART,	  risks	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remain	  elevated.17,18	  In	  CAP	  cohorts	  from	  the	  region,	  HIV	  prevalence	  of	  50	  to	  75%	  is	  typical,20-­‐24	  and	  
advanced	  HIV	  infection	  is	  frequently	  complicated	  by	  CAP	  despite	  the	  widespread	  rollout	  of	  ART.5	  	  
Exposure	  to	  household	  air-­‐pollution	  as	  a	  consequence	  of	  domestic	  combustion	  of	  biomass	  fuels	  for	  
heating,	  lighting	  and	  cooking	  has	  been	  causally	  linked	  to	  childhood	  pneumonia.	  Adults	  may	  also	  be	  at	  
risk	  from	  respiratory	  infections,25,26	  and	  this	  is	  the	  subject	  of	  current	  investigation.27	  Malnutrition	  and	  
household	  crowding	  may	  further	  contribute	  to	  the	  burden	  of	  pneumonia	  in	  the	  region.10,25,28	  The	  
combined	  effect	  of	  these	  risk	  factors	  mean	  that,	  in	  marked	  contrast	  to	  well-­‐resourced	  settings,	  CAP	  
cohorts	  in	  sub-­‐Saharan	  Africa	  are	  dominated	  by	  relatively	  young,	  working	  age	  patients.4,17,29,30	  
Outcome	  
The	  mortality	  rate	  of	  CAP	  varies	  markedly	  with	  disease	  severity	  and	  treatment	  setting,	  ranging	  from	  
<1%	  to	  nearly	  50%.31	  Differences	  in	  patient	  demographics	  and	  comorbidity	  profile	  and	  clinical	  
practice,	  particularly	  in	  terms	  of	  hospitalisation	  rate	  and	  intensive	  care	  referral,	  make	  direct	  
comparison	  between	  cohorts	  difficult.	  Crude	  mortality	  rates	  of	  adults	  hospitalised	  with	  pneumonia	  in	  
sub-­‐Saharan	  Africa	  (7-­‐14%)	  are	  comparable	  at	  to	  those	  reported	  from	  well-­‐resourced	  settings,	  despite	  
the	  average	  age	  of	  affected	  patients	  being	  much	  lower.20,24,32-­‐34	  
CAP	  cohorts	  from	  sub-­‐Saharan	  Africa	  typically	  report	  inpatient	  or	  30-­‐day	  mortality	  rates	  that	  may	  
substantially	  underestimate	  total-­‐pneumonia	  related	  mortality.	  In	  high-­‐income	  countries,	  after	  
apparent	  clinical	  resolution,	  survivors	  of	  CAP	  have	  an	  elevated	  risk	  of	  death	  for	  at	  least	  one	  year.35,36	  
One	  third	  of	  hospitalised	  CAP	  patients	  die	  within	  one	  year	  of	  hospital	  discharge.37	  This	  excess	  
mortality	  appears	  to	  be	  primarily	  driven	  by	  cardiovascular	  comorbidity.38	  There	  are	  no	  data	  on	  long-­‐
term	  mortality	  or	  symptomatic	  recovery	  following	  pneumonia	  in	  a	  sub-­‐Saharan	  African	  setting.	  
Aetiology	  
A	  huge	  number	  of	  microorganisms,	  including	  bacterial,	  viral	  and	  fungal	  pathogens,	  can	  cause	  CAP.	  In	  
most	  high	  income	  countries,	  the	  vast	  majority	  of	  cases	  are	  caused	  by	  one	  of:	  Streptococcus	  
pneumoniae;	  Haemophilus	  influenzae;	  Mycoplasma	  pneumoniae;	  Chlamydophila	  pneumoniae;	  
respiratory	  viruses;	  Legionella	  pneumophila;	  Staphylococcus	  aureus;	  Pseudomonas	  aeruginosa;	  Gram-­‐
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negative	  enteric	  bacilli.	  There	  are	  important	  geographical	  variations	  in	  the	  aetiological	  profile	  of	  CAP.	  
In	  areas	  of	  high	  incidence,	  Mycobacterium	  tuberculosis	  is	  common	  cause	  of	  acute	  CAP.24,39,40	  In	  South	  
Africa	  and	  many	  regions	  in	  Asia,	  hypervirulent	  strains	  of	  Klebsiella	  pneumoniae	  are	  frequent	  isolates	  
in	  severe	  CAP.41,42	  Burkholderia	  pseudomalleii,	  the	  causative	  agent	  of	  melioidosis,	  is	  endemic	  in	  
certain	  regions	  in	  South-­‐East	  Asia	  and	  may	  present	  as	  an	  acute	  pneumonic	  illness.43,44	  In	  sub-­‐Saharan	  
Africa	  the	  array	  of	  potential	  pathogens	  is	  broadened	  further	  still	  by	  high	  rates	  of	  HIV	  co-­‐infection.30	  	  
Bacterial	  pathogens	  
Streptococcus	  pneumoniae	  
Streptococcus	  pneumoniae	  is	  consistently	  the	  most	  commonly	  identified	  pathogen	  amongst	  
hospitalised	  patients	  with	  CAP	  globally,	  and	  in	  sub-­‐Saharan	  Africa	  where	  it	  accounts	  for	  at	  least	  one-­‐
quarter	  of	  all	  cases.45	  Relatively	  insensitive	  diagnostic	  tests,	  compounded	  by	  high	  rates	  of	  prior	  
antimicrobial	  use	  are	  likely	  to	  lead	  to	  substantial	  underestimation.46	  Scott	  et	  al.	  found	  evidence	  of	  
pneumococcal	  infection	  in	  46%	  of	  a	  large	  Kenyan	  CAP	  cohort	  using	  blood	  and	  urine	  antigen	  testing	  
and	  culture	  of	  percutaneous	  transthoracic	  lung	  aspirates	  in	  addition	  to	  standard	  techniques.24	  Using	  
the	  density	  of	  pneumococcal	  nasopharyngeal	  colonisation	  as	  a	  marker	  of	  pneumococcal	  disease	  in	  a	  
South	  African	  CAP	  cohort	  increased	  diagnostic	  rates	  from	  27%	  to	  53%.47	  	  
Gram-­‐negative	  bacteria	  
Gram-­‐negative	  pathogens	  represent	  a	  significant	  minority	  of	  CAP	  in	  sub-­‐Saharan	  Africa.	  Klebsiella	  
pneumoniae	  –	  typically	  implicated	  as	  a	  cause	  of	  hospital-­‐acquired	  pneumonia	  in	  well-­‐resourced	  
setting	  –	  is	  frequently	  seen	  in	  hospitalised	  CAP	  patients,	  accounting	  for	  up	  to	  19%	  of	  CAP	  in	  high	  
dependency	  settings	  in	  South	  Africa.21,48-­‐53	  	  
Invasive	  Salmonella	  infection	  is	  the	  commonest	  cause	  of	  bacteraemic	  illness	  in	  many	  sub-­‐Saharan	  
African	  settings.54	  HIV-­‐positive	  patients	  are	  susceptible	  to	  invasive	  infection	  with	  non-­‐typhoidal	  
salmonella	  species	  (S.	  enteritidis	  and	  S.	  typhimurium).	  CAP	  studies	  have	  reported	  Salmonella	  
infections	  in	  2-­‐10%	  of	  patients.24,55	  It	  is	  unclear	  whether	  the	  pneumonic	  illness	  represents	  primary	  
causation,	  or	  co-­‐infection	  with	  an	  undetected	  co-­‐pathogen,56	  although	  the	  therapeutic	  need	  for	  
broader	  spectrum	  antibiotics	  is	  the	  same.	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Atypical	  bacteria	  
The	  burden	  of	  adult	  pneumonia	  in	  sub-­‐Saharan	  Africa	  caused	  by	  so-­‐called	  atypical	  bacterial	  infections	  
(including	  Legionella	  spp.,	  Mycoplasma	  pneumoniae	  and	  Chlamydophila	  spp.)	  is	  poorly	  described.	  For	  
Mycoplasma	  and	  Chlamydophila,	  the	  few	  available	  studies	  are	  largely	  based	  on	  serological	  assays	  
using	  varying	  methods	  (e.g.	  ELISA,	  immunofluorescence,	  complement	  fixation)	  with	  incomplete	  
sampling	  frames;21,24,50,57,58	  estimated	  prevalence	  ranged	  from	  0-­‐9%	  and	  0-­‐21%,	  respectively.	  For	  
Legionella,	  studies	  that	  have	  in	  addition	  used	  a	  urinary	  antigen	  assay	  have	  estimated	  prevalence	  at	  2-­‐
9%.59,60	  Under-­‐ascertainment	  is	  possible	  however	  since	  the	  urinary	  antigen	  assay	  only	  reliably	  detects	  
L.	  pneumophila	  serogroup	  1	  and	  considerable	  geographical	  variation	  in	  the	  predominance	  of	  
particular	  Legionella	  species	  and	  serogroups	  has	  been	  reported.61,62	  	  
Influenza	  and	  other	  respiratory	  viruses	  
There	  are	  limited	  data	  from	  dedicated	  CAP	  cohorts	  describing	  the	  burden	  of	  viral	  pathogens	  in	  
hospitalised	  patients	  using	  modern	  molecular	  diagnostic	  tests.	  Using	  serological	  testing	  Scott	  et	  al.	  
identified	  a	  viral	  aetiology	  in	  6%	  of	  a	  cohort	  of	  Kenyan	  patients,	  the	  majority	  of	  which	  were	  cases	  of	  
influenza.24	  In	  a	  cohort	  of	  51	  Malawian	  patients	  with	  severe	  pneumonia,	  virus	  was	  identified	  by	  a	  
multiplex	  PCR	  assay	  of	  bronchoalveolar	  lavage	  (BAL)	  specimens	  in	  6%	  as	  the	  sole	  -­‐	  and	  presumed	  
causal	  -­‐	  pathogen	  and	  in	  16%	  as	  co-­‐infection	  typically	  with	  bacterial	  or	  Pneumocystis	  pneumonia.53	  By	  
comparison,	  a	  recent	  US	  CAP	  cohort	  found	  one	  or	  more	  viruses	  in	  23%	  of	  patients,	  most	  frequently	  
rhinovirus	  (9%),	  influenza	  (6%)	  and	  human	  metapneumovirus	  (4%).63	  Large	  scale	  community	  severe-­‐
acute	  respiratory	  illness	  (SARI)	  surveillance	  studies	  in	  sub-­‐Saharan	  Africa	  have	  similarly	  highlighted	  a	  
potentially	  much	  greater	  burden	  of	  circulating	  respiratory	  viral	  pathogens	  including	  influenza,	  
rhinovirus,	  respiratory	  syncytial	  virus,	  human	  metapneumovirus	  and	  adenovirus.64,65	  	  
Tuberculosis	  
Traditional	  teaching	  has	  attuned	  clinicians	  to	  suspecting	  pulmonary	  tuberculosis	  (TB)	  in	  patients	  with	  
prolonged	  symptoms	  -­‐	  typically	  a	  cough	  for	  longer	  than	  2	  weeks	  -­‐	  and	  this	  group	  has	  historically	  been	  
the	  focus	  of	  TB	  diagnostic	  services	  in	  high	  burden	  settings.66	  In	  sub-­‐Saharan	  Africa,	  TB	  is	  consistently	  
reported	  as	  a	  cause	  of	  illness	  in	  patients	  presenting	  with	  CAP	  symptoms,	  signs	  and	  radiology,	  and	  with	  
shorter	  duration	  of	  illness.24,67	  Overall	  M.	  tuberculosis	  is	  identified	  in	  9	  to	  25%	  of	  CAP,	  with	  rates	  in	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HIV-­‐infected	  patients	  typically	  higher.21,24,53,68	  Microbiological	  testing	  of	  samples	  from	  bronchoscopy	  
has	  identified	  similar	  proportions:	  CAP	  cohorts	  from	  Central	  African	  Republic,	  Senegal,	  South	  Africa	  
and	  Malawi	  estimate	  rates	  from	  13%	  to	  29%.21,51,53,68	  In	  HIV	  co-­‐infection,	  using	  rigorous	  TB	  diagnostic	  
algorithms	  with	  intensive	  specimen	  collection,	  up	  to	  one-­‐third	  of	  all	  HIV-­‐positive	  acute	  medical	  in-­‐
patients	  are	  found	  to	  have	  TB	  in	  South	  Africa,	  Zambia	  and	  Malawi.69-­‐71	  In	  post	  mortem	  series	  of	  HIV-­‐
infected	  medical	  in-­‐patients	  as	  many	  as	  62%	  have	  TB.72	  
Pneumocystis	  jirovecii	  pneumonia	  
In	  US	  and	  European	  cohorts,	  Pneumocystis	  jirovecii	  (formerly	  P.	  carinii)	  pneumonia	  (PCP)	  is	  the	  
commonest	  opportunistic	  infection	  in	  individuals	  with	  advanced	  HIV.73,74	  Historically,	  the	  reported	  
burden	  of	  HIV-­‐related	  PCP	  in	  sub-­‐Saharan	  Africa	  has	  been	  considerably	  lower,75-­‐77	  although	  the	  
causative	  protozoan	  is	  ubiquitous.	  These	  lower	  rates	  may	  be	  partly	  attributable	  to	  early	  mortality	  
from	  more	  rapidly	  progressive	  infections.	  However,	  ascertainment	  bias	  is	  likely	  in	  the	  absence	  of	  
sensitive	  diagnostic	  tests.78,79	  Difficulties	  of	  specimen	  collection	  from	  bronchoscopy	  are	  also	  likely	  to	  
cause	  selection	  bias	  due	  to	  under-­‐sampling	  of	  critically	  unwell	  patients.79	  When	  performed,	  
bronchoscopy	  studies	  from	  African	  centres	  have	  demonstrated	  a	  considerable	  burden	  of	  PCP	  
amongst	  HIV-­‐infected	  patients	  with	  features	  of	  respiratory	  infection.53,80-­‐82	  Amongst	  patients	  with	  CAP	  
estimates	  of	  the	  burden	  of	  PCP	  vary	  considerably	  ranging	  from	  2%	  in	  general	  hospital	  inpatient	  
cohorts	  to	  27%	  amongst	  patients	  admitted	  to	  high	  dependency	  unit.51,53,68,83	  
Approach	  to	  clinical	  assessment	  
Diagnosis	  
A	  number	  of	  conventions	  frequently	  define	  studies	  of	  respiratory	  infection:	  1)	  the	  standardised	  
definition	  of	  pneumonia	  typically	  requires	  radiological	  evidence	  of	  an	  infiltrate	  (e.g.	  on	  plain	  
posteroanterior	  chest	  radiograph);	  2)	  pneumonia	  is	  distinguished	  from	  acute	  bronchitis	  and	  infective	  
exacerbations	  of	  COPD,	  where	  chest	  X-­‐ray	  changes	  are	  not	  required	  for	  diagnosis;	  3)	  pneumonia	  in	  
immunocompromised	  patients	  is	  generally	  considered	  separately	  because	  of	  the	  broader	  spectrum	  of	  
pathogens;	  4)	  TB	  is	  differentiated	  from	  CAP	  rather	  than	  regarded	  as	  its	  cause.	  These	  conventions	  have	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led	  CAP	  management	  guidelines	  in	  high	  income	  countries	  to	  restrict	  their	  scope	  to	  tightly	  defined	  
presentations	  of	  CAP	  which	  do	  not	  fully	  represent	  the	  spectrum	  of	  disease	  elsewhere.	  This	  diagnostic	  
framework	  for	  pneumonia	  needs	  to	  be	  re-­‐considered	  in	  sub-­‐Saharan	  African	  settings	  where	  the	  
majority	  of	  CAP	  cases	  occur	  in	  HIV-­‐positive	  (i.e.	  immunocompromised)	  individuals.	  Here,	  radiographic	  
changes	  for	  certain	  pathogens	  may	  be	  atypical	  (e.g.	  the	  classical	  upper	  zone	  infiltration	  of	  
tuberculosis	  is	  found	  less	  frequently).84	  Opportunistic	  pathogens	  such	  as	  Pneumocystis	  often	  have	  
only	  subtle	  changes	  on	  plain	  chest	  radiography85	  which	  is	  inconsistently	  interpreted.86,87	  In	  many	  
settings,	  chest	  radiography	  is	  not	  immediately	  available	  or	  these	  resources	  might	  be	  deliberately	  
restricted	  for	  those	  failing	  to	  respond	  to	  treatment.88,89	  In	  community	  settings,	  the	  first	  level	  
healthcare	  workers	  or	  lay-­‐providers	  may	  not	  have	  been	  trained	  to	  perform	  chest	  auscultation.88	  
World	  Health	  Organization	  (WHO)	  treatment	  guidelines	  for	  resource-­‐limited	  settings	  therefore	  use	  a	  
clinical	  definition	  of	  pneumonia	  of	  cough	  associated	  with	  two	  of	  fever/night	  sweats,	  tachypnoea	  or	  
chest	  pain.88,89	  	  
Severity	  assessment	  
CAP	  guidelines	  recommend	  that	  initial	  management	  decisions,	  such	  as	  site	  of	  care	  and	  choice	  of	  
antimicrobial,	  are	  guided	  by	  an	  objective	  assessment	  of	  disease	  severity	  made	  using	  a	  validated	  
tool.90,91	  More	  than	  a	  dozen	  CAP	  severity	  assessment	  tools	  have	  been	  developed,	  but	  almost	  
universally	  derive	  from	  patients	  in	  well-­‐resourced	  settings	  without	  immunocompromise.92,93	  Given	  
differences	  in	  demographics,	  comorbidity	  profile,	  and	  disease	  aetiology,	  extrapolation	  beyond	  these	  
cohorts	  should	  be	  cautioned.	  Relevant	  data	  from	  sub-­‐Saharan	  Africa	  are	  limited.	  In	  a	  small	  cohort	  of	  
88	  patients	  from	  Nigeria,	  30-­‐day	  mortality	  rose	  with	  CURB65	  and	  at	  a	  threshold	  score	  of	  3	  or	  more,	  
reported	  sensitivity	  and	  specificity	  were	  80%	  and	  97%,	  respectively.94	  In	  a	  well-­‐characterised	  cohort	  
of	  280	  HIV-­‐infected	  patients	  with	  radiographic	  CAP	  from	  South	  Africa,	  Albrich	  et	  al.	  found	  CURB65	  
was	  not	  a	  useful	  discriminator	  of	  in-­‐hospital	  mortality	  for	  either	  all	  CAP	  patients	  or	  those	  with	  
confirmed	  pneumococcal	  pneumonia.22	  Similarly,	  CRB65	  (the	  abbreviated	  version	  of	  CURB65	  that	  
does	  not	  require	  laboratory	  urea	  measurement)	  showed	  only	  moderate	  discriminative	  capability	  (i.e.	  
CRB65	  ≥2:	  sensitivity	  36%;	  specificity	  81%;	  positive	  predictive	  value	  30%;	  negative	  predictive	  value	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85%;	  AUROC	  0.65)	  for	  predicting	  inpatient	  mortality	  in	  a	  cohort	  of	  patients	  with	  clinically	  defined	  
pneumonia	  from	  Malawi.	  	  
Several	  authors	  have	  attempted	  to	  derive	  tools	  better	  suited	  for	  use	  in	  sub-­‐Saharan	  African	  
populations.	  Birkhamshaw	  et	  al.	  reported	  that	  a	  novel	  severity	  score,	  termed	  SWAT-­‐Bp,	  based	  on	  the	  
presence	  of	  male	  sex,	  wasting,	  inability	  to	  stand,	  pyrexia/hypothermia	  and	  low	  blood	  pressure	  
outperformed	  CRB65	  in	  predicting	  in-­‐hospital	  mortality	  (SWAT-­‐Bp	  ≥3:	  sensitivity	  84%;	  specificity	  77%;	  
positive	  predictive	  value	  45%;	  negative	  predictive	  value	  96%;	  AUROC	  0.65).23	  In	  a	  cohort	  of	  HIV-­‐
infected	  patients	  from	  Uganda	  with	  cough	  for	  greater	  than	  two	  weeks	  and	  clinically	  suspected	  
pneumonia,	  Koss	  et	  al.	  suggested	  an	  alternative	  severity-­‐assessment	  tool	  based	  on	  tachycardia,	  
tachypnoea,	  hypoxaemia	  and	  low	  CD4	  count.95	  These	  small	  studies	  demonstrate	  that	  there	  is	  
considerable	  potential	  for	  improving	  severity	  assessment,	  and	  that	  tools	  should	  be	  revalidated	  when	  
adopted	  in	  new	  settings.	  
Establishing	  aetiological	  diagnosis	  
General	  considerations	  
Aetiological	  confirmation	  of	  CAP	  is	  challenging.	  Even	  in	  a	  recent	  prospective	  cohort	  study	  in	  the	  US	  
that	  used	  extensive	  testing	  and	  multiple	  assays,	  pathogens	  where	  identified	  in	  only	  38%.63	  In	  routine	  
clinical	  practice	  the	  proportion	  is	  much	  lower.96	  In	  well-­‐resourced	  settings,	  CAP	  guidelines	  
recommend	  that	  selection	  of	  empirical	  antimicrobial	  therapy	  is	  based	  on	  severity	  assessment,	  and	  
modified	  by	  risk	  factors	  for	  resistant	  organisms.90,91,97	  Concordance	  with	  antimicrobial	  treatment	  
guidelines	  is	  associated	  with	  improved	  outcome,98	  and	  the	  use	  of	  antigen	  testing	  (for	  S.	  pneumoniae	  
and	  L.	  pneumophila)	  for	  early	  targeted	  (pathogen-­‐directed)	  antimicrobial	  treatment	  has	  so	  far	  failed	  
to	  demonstrate	  significant	  benefit	  to	  patient	  management	  or	  clinical	  outcome.99	  In	  many	  sub-­‐Saharan	  
African	  settings,	  however,	  to	  give	  adequate	  antimicrobial	  cover	  for	  all	  likely	  pathogens	  empirical	  CAP	  
therapy	  would	  often	  have	  to	  include	  treatment	  for	  both	  TB	  and	  PCP.	  A	  pathogen-­‐directed	  approach,	  
at	  least	  to	  the	  level	  of	  distinguishing	  bacterial	  pneumonia	  from	  TB	  and	  PCP	  is	  likely	  to	  be	  beneficial.100	  
However,	  the	  laboratory	  infrastructure	  to	  support	  diagnostic	  microbiological	  in	  many	  sub-­‐Saharan	  
African	  settings	  is	  weak	  or	  limited.89	  Bacteriological	  culture	  or	  molecular	  techniques	  that	  form	  the	  
mainstay	  of	  CAP	  diagnostics	  in	  well-­‐resourced	  settings	  are	  often	  lacking	  and	  may	  not	  be	  sustainable	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outside	  of	  referral	  hospital	  or	  research	  laboratories:	  point-­‐of-­‐care	  or	  rapid	  diagnostic	  tests	  have	  great	  
potential	  in	  these	  settings.	  
Streptococcus	  pneumoniae	  
The	  Alere	  BinaxNOW	  Streptococcus	  pneumoniae	  antigen	  card	  is	  a	  lateral	  flow	  assay	  that	  detects	  
pneumococcal	  antigens	  in	  urine	  requiring	  minimal	  laboratory	  infrastructure.101	  In	  adults	  in	  well-­‐
resourced	  settings,	  it	  may	  be	  used	  to	  diagnose	  pneumococcal	  CAP	  with	  reasonable	  accuracy	  (overall	  
sensitivity	  and	  specificity	  74%	  and	  97%,	  respectively),	  but	  in	  children	  lacks	  specificity	  due	  to	  high	  rates	  
of	  pneumococcal	  nasopharyngeal	  colonisation.102,103	  In	  low-­‐resource	  sub-­‐Saharan	  African	  settings,	  
pneumococcal	  nasopharyngeal	  colonisation	  is	  common	  in	  adults	  also.	  The	  limited	  available	  data	  
indicate	  that	  specificity	  of	  BinaxNOW	  S.	  pneumoniae	  assay	  in	  adults	  is	  not	  affected	  by	  nasopharyngeal	  
colonisation,104	  but	  the	  impact	  of	  concurrent	  HIV	  infection	  and	  pneumococcal	  colonisation	  has	  not	  
been	  analysed.	  When	  used	  in	  CAP	  studies	  in	  sub-­‐Saharan	  Africa,	  it	  increases	  the	  proportion	  of	  cases	  
attributable	  to	  S.	  pneumonia.47,105	  The	  practical	  value	  of	  a	  test	  that	  confirms	  pneumococcal	  aetiology	  
in	  this	  setting	  is	  uncertain:	  recommended	  empirical	  CAP	  therapy	  always	  includes	  anti-­‐pneumococcal	  
cover	  and	  in	  this	  setting	  a	  positive	  result	  would	  not	  obviate	  the	  need	  to	  exclude	  co-­‐infections	  such	  as	  
TB.106,107	  	  
Tuberculosis	  
Until	  recently,	  smear	  microscopy	  and	  chest	  radiography	  were	  the	  mainstay	  investigations	  for	  the	  
acute	  diagnosis	  of	  TB	  but	  both	  had	  poor	  sensitivity,	  particularly	  in	  concurrent	  HIV	  infection.108,109	  The	  
automated	  Cepheid	  Xpert	  MTB/RIF	  platform	  can	  identify	  Mycobacterium	  tuberculosis	  and	  common	  
rifampicin	  resistance	  genotypes	  from	  unprocessed	  sputum	  specimens	  in	  less	  than	  two	  hours.110	  Since	  
2010,	  this	  platform	  has	  been	  rolled-­‐out	  to	  many	  low-­‐	  and	  middle-­‐income	  countries	  where	  it	  is	  
frequently	  the	  central	  pillar	  of	  TB	  diagnostics.111	  Compared	  to	  the	  gold-­‐standard	  diagnostic	  test	  of	  
sputum	  culture,	  Xpert	  MTB/RIF	  has	  an	  overall	  sensitivity	  of	  88%	  and	  specificity	  of	  98%.112	  In	  HIV-­‐
associated	  TB,	  the	  sensitivity	  of	  Xpert	  MTB/RIF	  is	  estimated	  at	  84%.110	  	  
The	  recently	  developed	  Alere	  Determine	  TB	  LAM	  Ag	  is	  a	  point-­‐of-­‐care	  test	  assay	  that	  detects	  the	  
mycobacterial	  cell	  wall	  glycopeptide	  lipoarabinomannan	  (LAM)	  in	  urine,	  and	  provides	  an	  incremental	  
increase	  in	  sensitivity	  over	  sputum	  smear	  microscopy	  alone.113,114	  Diagnostic	  yield	  is	  higher	  in	  the	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most	  highly	  immunocompromised	  patients	  and	  those	  with	  features	  of	  severe	  disease	  (e.g.	  anaemia,	  
elevated	  CRP)	  at	  greatest	  risk	  of	  death,	  where	  it	  probably	  represents	  diagnosis	  of	  disseminated	  TB	  
disease.115-­‐117	  Use	  of	  the	  test	  to	  guide	  initiation	  of	  anti-­‐tuberculous	  is	  associated	  with	  a	  17%	  relative	  
reduction	  in	  mortality	  compared	  to	  standard	  diagnostic	  strategy.118	  	  
Pneumocystis	  jirovecii	  	  
Definitive	  diagnosis	  of	  PCP	  relies	  on	  detection	  of	  Pneumocystis	  either	  by	  microscopy	  or	  molecular	  
techniques	  in	  bronchoalveolar	  lavage	  fluid	  or	  induced	  sputum.	  The	  current	  availability	  of	  PCR	  assays	  
with	  improved	  sensitivity	  may	  permit	  the	  use	  of	  more	  readily	  obtained	  non-­‐invasive	  specimens	  such	  
as	  expectorated	  sputum119	  or	  nasopharyngeal	  aspirates,120	  where	  Pneumocystis	  organisms	  are	  
present	  in	  lower	  concentrations.	  Although	  there	  is	  currently	  no	  analogue	  of	  the	  Xpert	  MTB/RIF	  for	  
PCP	  that	  permits	  rapid	  detection	  of	  DNA	  in	  unprocessed	  clinical	  specimens.	  An	  alternative	  strategy	  is	  
based	  on	  detection	  of	  the	  fungal	  cell	  wall	  component	  1-­‐3-­‐β-­‐D-­‐glucan	  in	  serum.121	  Several	  studies	  have	  
indicated	  that	  serum	  1-­‐3-­‐β-­‐D-­‐glucan	  has	  excellent	  (>95%)	  sensitivity	  and	  reasonable	  specificity	  (84-­‐
86%)	  for	  detecting	  PCP	  in	  patients	  with	  both	  HIV	  and	  other	  forms	  of	  immunocompromise.122,123	  
However,	  currently	  available	  assays	  are	  based	  on	  photometric	  methods	  that	  require	  considerable	  
manual	  processing	  and	  dedicated	  equipment	  that	  would	  preclude	  use	  in	  many	  low-­‐resource	  setting	  
clinical	  laboratories.	  
Alternative	  approaches	  
In	  the	  absence	  of	  a	  confirmed	  microbiological	  diagnosis,	  radiographic	  and	  laboratory	  indices	  are	  
sometimes	  used	  to	  infer	  aetiology	  and	  guide	  therapy	  in	  routine	  clinical	  practice.124	  There	  are	  well	  
described	  associations	  of	  aetiology	  with	  radiographic	  appearance:	  upper	  lobe	  consolidation,	  
cavitation,	  unilateral	  pleural	  effusion	  and	  lymphadenopathy	  are	  associated	  with	  TB;125	  diffuse	  
bilateral	  fine	  or	  ground	  glass	  shadowing	  is	  typical	  of	  PCP.81,126	  However,	  these	  associations	  are	  not	  
strong	  enough	  to	  discriminate	  to	  impact	  clinical	  practice	  and	  chest	  radiograph	  features	  vary	  with	  
immune	  status	  in	  HIV-­‐infected	  patients.84	  	  
In	  HIV-­‐positive	  patients,	  the	  sequence	  of	  pulmonary	  complications	  parallels	  the	  depletion	  of	  CD4	  
cells;	  bacterial	  pneumonia	  and	  TB	  become	  more	  common	  from	  early	  in	  the	  disease	  course	  when	  CD4	  
counts	  are	  well-­‐preserved,	  whilst	  PCP	  and	  other	  opportunistic	  pathogens	  are	  generally	  only	  seen	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when	  CD4	  counts	  fall	  below	  200	  cells/mL.30,127	  However,	  in	  acute	  illness,	  CD4	  counts	  may	  fall	  
substantially,128,129	  and	  therefore	  cannot	  accurately	  infer	  the	  stage	  of	  HIV	  illness	  or	  inform	  the	  likely	  
spectrum	  of	  pathogens	  during	  an	  episode	  of	  pneumonia.	  
Inflammatory	  biomarkers	  such	  as	  procalcitonin	  (PCT)	  or	  C-­‐reactive	  protein	  (CRP)	  are	  increasingly	  
being	  used	  in	  well-­‐resourced	  settings	  to	  guide	  the	  management	  of	  respiratory	  infection.130	  Combining	  
PCT	  or	  CRP	  measurements	  with	  clinical	  assessment	  improves	  accuracy	  for	  diagnosing	  radiographic	  
CAP.131	  Total	  antibacterial	  exposure	  and	  median	  duration	  of	  therapy	  may	  be	  safely	  reduced	  without	  
compromising	  clinical	  outcomes	  using	  PCT-­‐guided	  algorithms.132	  In	  a	  sub-­‐Saharan	  African	  setting,	  
limited	  data	  suggest	  that	  PCT	  may	  be	  useful	  in	  distinguishing	  bacterial	  pneumonia	  from	  other	  causes.	  




Initial	  antimicrobial	  therapy	  in	  CAP	  is	  almost	  always	  empirical,	  and	  should	  be	  based	  on	  severity.90,91,97	  
In	  severe	  CAP,	  broad-­‐spectrum	  antimicrobials	  are	  used	  to	  give	  immediate	  cover	  for	  all	  probable	  
pathogens.	  These	  include	  Staphylococcus	  aureus,	  Gram-­‐negative	  enteric	  bacteria,	  Legionella	  
pneumophila	  and	  in	  some	  cases	  Pseudomonas	  aeruginosa.	  Extended	  microbiological	  investigations	  
are	  promoted	  as	  a	  method	  of	  early	  rationalisation	  of	  treatment.130	  
In	  high-­‐income	  countries,	  mild	  disease	  is	  usually	  treated	  with	  narrower	  spectrum	  agents,	  although	  
there	  is	  significant	  variation	  in	  recommendations	  for	  cover	  of	  “atypical”	  organisms.	  Using	  this	  
approach,	  therapy	  is	  broadened	  in	  the	  event	  of	  clinical	  failure.	  	  
Adopting	  similar	  approaches	  in	  many	  sub-­‐Saharan	  African	  settings	  presents	  difficulties.	  By	  default,	  a	  
“step-­‐up”	  approach	  is	  taken	  where	  by	  clinical	  non-­‐response	  on	  broad-­‐spectrum	  antibacterials	  results	  
in	  sequential	  addition	  of	  other	  agents,	  such	  as	  antimycobacterials	  and	  antifungals.	  This	  limits	  the	  use	  
of	  expensive	  and	  complex	  treatment,	  but	  may	  miss	  the	  opportunity	  for	  early	  gains	  from	  aggressive	  
therapy.	  
CAP	  in	  sub-­‐Saharan	  Africa	   	   Aston,	  Rylance	  
	   13	  
WHO	  and	  African	  treatment	  guidelines	  
The	  WHO	  Integrated	  Management	  of	  Adolescent	  and	  Adult	  Illness	  (IMAI)	  guidelines	  were	  devised	  to	  
provide	  general	  recommendations	  for	  disease	  management	  in	  resource-­‐limited	  settings	  and	  improve	  
healthcare	  at	  facility	  level.88,89	  
For	  those	  with	  severe	  pneumonia,	  IMAI	  guidelines	  recommend	  ceftriaxone	  (or	  ampicillin	  and	  
gentamicin)	  plus	  a	  macrolide.89	  South	  African	  guidelines	  suggest	  the	  use	  of	  gentamicin	  (or	  another	  
aminoglycoside)	  in	  view	  of	  the	  high	  frequency	  of	  CAP	  due	  to	  Gram-­‐negative	  bacilli,	  especially	  
Klebsiella.124	  In	  high	  TB	  burden	  settings,	  the	  WHO	  approach	  to	  severe	  CAP	  is	  to	  first	  trial	  broad	  
spectrum	  antibacterials,	  and	  introduce	  empirical	  TB	  treatment	  at	  3	  days	  where	  improvement	  is	  not	  
evident.134	  This	  approach	  misses	  20%	  of	  patients	  with	  retrospectively	  culture-­‐proven	  TB	  and	  risks	  
delaying	  treatment	  in	  a	  group	  of	  patients	  with	  a	  high	  risk	  of	  early	  death.135	  Early	  empirical	  TB	  for	  high-­‐
risk	  patients	  is	  the	  focus	  of	  current	  research.136,137	  	  	  
For	  HIV-­‐positive	  patients,	  IMAI	  guidelines	  recommend	  that	  high	  dose	  co-­‐trimoxazole	  for	  treatment	  of	  
PCP	  is	  added	  for	  all	  patients	  with	  severe	  pneumonia.89	  South	  African	  guidelines	  modify	  this	  
recommendation,	  advising	  empirical	  PCP	  treatment	  where	  the	  chest	  radiograph	  is	  suggestive	  (i.e.	  
bilateral	  infiltrates).124	  Antimicrobial	  guidelines	  in	  other	  sub-­‐Saharan	  African	  countries	  also	  differ.	  In	  
Malawi	  an	  initial	  regimen	  of	  ceftriaxone	  or	  a	  combination	  of	  penicillin	  plus	  chloramphenicol	  is	  
recommended.	  A	  macrolide,	  gentamicin	  and	  consideration	  of	  PCP	  treatment	  are	  advised	  for	  patients	  
not	  improving	  at	  48	  hours.138	  	  
For	  non-­‐severe	  pneumonia,	  IMAI	  recommends	  monotherapy	  with	  oral	  amoxicillin.	  South	  African	  
guidelines	  differ,	  recommending	  that	  atypical	  cover	  in	  the	  form	  of	  a	  macrolide	  or	  doxycycline	  is	  also	  
used	  for	  all	  patients.	  For	  elderly	  patients	  or	  those	  with	  comorbid	  illness,	  these	  recommend	  that	  
amoxicillin	  is	  replaced	  by	  co-­‐amoxiclav	  or	  a	  cephalosporin	  to	  provide	  broader	  antimicrobial	  cover.124	  
In	  South	  African	  guidelines,	  macrolide	  monotherapy	  is	  avoided	  because	  of	  concerns	  about	  resistance	  
in	  S.	  pneumoniae.139	  In	  view	  of	  their	  potent	  anti-­‐tuberculous	  activity,	  fluoroquinolones	  should	  be	  used	  
with	  caution	  in	  high	  TB-­‐burden	  settings,	  since	  empirical	  use	  of	  may	  lead	  to	  delayed	  diagnosis	  of	  TB	  
and	  a	  higher	  risk	  of	  subsequently	  developing	  fluoroquinolone-­‐resistant	  TB.140,141	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Supportive	  management	  
Supportive	  therapy	  for	  pneumonia	  in	  adults	  in	  sub-­‐Saharan	  Africa	  is	  driven	  by	  consensus	  guidelines.	  	  
Intravenous	  fluids	  
Respiratory	  infection	  accounts	  for	  more	  than	  half	  of	  sepsis.142	  For	  patients	  manifesting	  sepsis	  in	  high	  
resource	  settings,	  early	  goal	  directed	  therapy	  (EGDT)	  has	  been	  the	  dominant	  recent	  theme.	  
Aggressive	  fluid	  management	  and	  goal-­‐orientated	  therapy	  have	  become	  accepted	  practice	  due	  to	  
positive	  findings	  from	  early	  landmark	  studies,143	  and	  are	  supported	  by	  meta-­‐analysis	  showing	  
mortality	  reductions	  (OR	  0.64;	  95%	  CI:	  0.43-­‐0.96).144	  
Data	  from	  sub-­‐Saharan	  Africa	  on	  early	  supportive	  management	  of	  sepsis	  are	  scarce.	  In	  a	  “before	  and	  
after”	  Ugandan	  study	  of	  adults,	  headline	  mortality	  reduced	  from	  45	  to	  33%	  over	  2	  years	  after	  the	  
employment	  of	  dedicated	  medical	  officers	  to	  oversee	  early	  sepsis	  treatment.	  Median	  intravenous	  
fluid	  administered	  in	  the	  first	  6	  hours	  increased	  from	  500ml	  to	  3000ml145	  but	  there	  was	  no	  dose	  
response	  above	  1000ml.	  In	  a	  Zambian	  randomised	  controlled	  trial	  of	  a	  simplified	  EGDT	  protocol,	  the	  
volume	  of	  intravenous	  fluid	  administered	  was	  greater	  in	  the	  intervention	  group	  (2800	  mL	  vs.	  1600	  
mL),	  but	  this	  group	  encompassed	  people	  with	  normal	  blood	  pressure.146	  This	  trial	  was	  stopped	  early	  
because	  of	  high	  overall	  in-­‐hospital	  mortality	  (62.4%),	  particularly	  in	  patients	  with	  hypoxaemic	  
respiratory	  failure.	  
The	  paediatric	  FEAST	  study	  similarly	  demonstrated	  higher	  mortality	  in	  septic	  children	  treated	  with	  
aggressive	  fluid	  resuscitation.147	  Bolus	  fluids	  were	  associated	  with	  early	  improvements	  in	  shock,	  but	  
later	  increased	  risks	  of	  cardiovascular	  collapse	  and	  mortality.148	  
Recommendations	  for	  fluid	  therapy	  in	  adults	  in	  sub-­‐Saharan	  Africa	  are	  therefore	  fraught	  with	  
uncertainty.	  Maintenance	  fluids	  should	  be	  prescribed	  to	  those	  who	  cannot	  maintain	  oral	  intake.	  
Boluses	  totalling	  more	  than	  20ml/kg	  should	  be	  used	  with	  caution,	  particularly	  in	  settings	  lacking	  
critical	  care	  facilities.	  
Oxygen	  
Hypoxia	  is	  an	  independent	  predictor	  of	  mortality	  in	  adults	  with	  sepsis	  and	  pneumonia.95,149	  During	  
admission	  to	  a	  hospital	  in	  Kigali,	  Rwanda,	  12%	  required	  oxygen,	  as	  defined	  by	  resting	  saturations	  
CAP	  in	  sub-­‐Saharan	  Africa	   	   Aston,	  Rylance	  
	   15	  
(SpO2)	  of	  less	  than	  90%	  on	  air)	  at	  some	  point.
150	  Of	  those	  whose	  SpO2	  did	  not	  increase	  with	  therapy,	  
mortality	  was	  increased,	  but	  small	  numbers	  made	  the	  confidence	  margins	  wide.	  
Programmatic	  interventions	  in	  children	  based	  on	  improved	  oxygen	  supply	  using	  concentrators	  have	  
been	  associated	  with	  a	  35%	  reduction	  in	  mortality	  (in	  Papua	  New	  Guinea),151	  and	  paediatric	  studies	  of	  
oxygen	  therapy	  for	  pneumonia	  are	  numerous,	  although	  commonly	  have	  no	  comparison	  or	  control	  
group.152	  The	  randomised	  controlled	  COAST	  trial	  (ISRCTN15622505)	  is	  currently	  investigating,	  in	  
Africa,	  high	  flow	  oxygen	  compared	  with	  standard	  therapy.	  	  
In	  the	  absence	  of	  randomised	  controlled	  trial	  evidence	  in	  adults,	  British	  Thoracic	  Society	  guidelines	  
suggest	  to	  maintain	  SpO2	  between	  94%	  and	  98%.
153	  Oxygen	  supply	  and	  delivery	  infrastructure	  is	  
inadequate	  in	  many	  healthcare	  facilities	  across	  sub-­‐Saharan	  Africa.154	  In	  the	  absence	  of	  piped	  oxygen	  
infrastructure,	  low-­‐flow	  (around	  5	  L/min)	  mains-­‐powered	  oxygen	  concentrators	  are	  the	  mainstay	  of	  
oxygen	  provision,	  although	  cylinders	  may	  be	  preferable	  in	  specific	  situations.155	  Descriptions	  of	  
performance	  and	  robustness	  of	  oxygen	  concentrator	  models	  have	  been	  published,156	  but	  data	  on	  
their	  effectiveness	  for	  correcting	  hypoxia	  in	  acutely	  ill	  adults	  or	  improving	  outcomes	  is	  lacking.	  	  
Ventilatory	  support	  
The	  lack	  of	  adequately	  staffed	  critical	  care	  units	  means	  that	  invasive	  positive	  pressure	  ventilation	  
(IPPV)	  is	  confined	  mostly	  to	  regional	  centres	  in	  Africa.	  There	  is	  a	  lack	  of	  evidence	  surrounding	  the	  
cost-­‐effectiveness	  of	  highly	  resource-­‐intensive	  therapies	  such	  as	  IPPV.	  Meta-­‐analysis	  of	  non-­‐invasive	  
ventilation	  in	  pneumonia	  in	  high	  resource	  settings	  has	  not	  demonstrated	  any	  mortality	  benefit,	  but	  
did	  show	  a	  reduction	  in	  intubation	  rates.157	  
Steroids	  
Meta-­‐analysis	  of	  trials	  of	  adjunct	  corticosteroids	  in	  CAP	  has	  not	  shown	  any	  mortality	  benefit,	  but	  
demonstrated	  a	  reduction	  in	  hospital	  stays	  and	  ARDS	  rates	  in	  high	  resource	  settings.158	  As	  a	  result	  of	  
corticosteroid	  treatment,	  the	  largest	  trial	  (from	  Switzerland)	  reported	  an	  8%	  absolute	  increase	  in	  the	  
number	  of	  patients	  requiring	  insulin	  treatment	  for	  hyperglycaemia.159	  In	  resource	  limited	  settings	  
with	  high	  rates	  of	  HIV,	  corticosteroids	  may	  also	  be	  indicated	  for	  severe	  PCP.	  However,	  there	  is	  no	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evidence	  supporting	  their	  use	  in	  pneumonia,	  and	  only	  one	  trial	  investigated	  this,	  in	  the	  setting	  of	  ITU	  
in	  South	  Africa.160	  
Prevention	  
The	  opportunities	  for	  CAP	  prevention	  in	  sub-­‐Saharan	  Africa	  are	  substantial.	  Antiretroviral	  therapy	  
(ART)	  markedly	  reduces	  the	  risk	  of	  pneumonia	  and	  early	  initiation	  improves	  survival.161,162	  The	  rapid	  
roll-­‐out	  of	  ART	  in	  sub-­‐Saharan	  Africa	  has	  been	  a	  huge	  public	  health	  success	  with	  more	  than	  9.1	  million	  
started	  on	  treatment,163	  but	  the	  challenges	  of	  timely	  HIV	  diagnosis	  and	  prompt	  initiation	  of	  ART	  
remain.	  Average	  CD4	  cell	  counts	  at	  presentation	  and	  ART	  initiation	  are	  low	  at	  251	  and	  152	  cells/mm3	  
respectively.164	  The	  recent	  shift	  of	  WHO	  policy	  to	  universal	  ART	  for	  all	  HIV-­‐infected	  patients	  regardless	  
of	  CD4	  count	  may	  be	  beneficial.165	  	  	  
Co-­‐trimoxazole	  preventative	  therapy	  (CPT)	  continues	  to	  reduce	  the	  risk	  of	  hospitalisation	  and	  
pneumonia	  after	  ART	  initiation.166	  Isoniazid	  preventative	  therapy	  (IPT)	  also	  provides	  an	  additive	  
benefit	  over	  ART,	  reducing	  incident	  TB	  cases	  by	  as	  much	  as	  43%	  in	  high	  burden	  settings,167,168	  but	  to	  
date	  has	  been	  widely	  underutilised	  in	  sub-­‐Saharan	  Africa.	  A	  single	  fixed-­‐dose	  pill	  combining	  both	  co-­‐
trimoxazole	  and	  isoniazid	  is	  currently	  in	  development.169	  
The	  13-­‐valent	  pneumococcal	  conjugate	  vaccine	  (PCV)	  has	  proven	  effectiveness	  to	  protect	  against	  
invasive	  pneumococcal	  disease	  (IPD)	  in	  HIV-­‐infected	  patients170	  and	  pneumococcal	  pneumonia	  in	  
elderly	  adults.171	  In	  the	  US	  and	  UK,	  infant	  vaccination	  has	  indirect	  positive	  effects	  on	  disease	  in	  adult	  
populations.172,173	  Universal	  infant	  PCV	  has	  recently	  been	  introduced	  in	  many	  countries	  across	  sub-­‐
Saharan	  Africa.	  The	  extent	  of	  indirect	  effects,	  particularly	  in	  HIV-­‐infected	  adults,	  is	  as	  yet	  unclear	  and	  
needs	  careful	  study	  to	  determine	  whether	  the	  burden	  of	  residual	  vaccine-­‐serotype	  disease	  warrants	  
additional	  targeted	  vaccination	  programmes.	  
Research	  priorities	  
Epidemiology	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The	  burden	  of	  pneumococcal	  disease	  and	  TB	  is	  consistently	  demonstrated	  in	  CAP	  cohorts	  from	  across	  
sub-­‐Saharan	  Africa.	  Rates	  of	  PCP,	  however,	  are	  much	  more	  variably	  estimated:	  27%	  in	  critically	  unwell	  
patients	  in	  Malawi,53	  39%	  in	  those	  with	  non-­‐responsive	  pulmonary	  symptoms	  attending	  for	  
bronchoscopy	  in	  Uganda82	  whilst	  other,	  less	  selected,	  cohorts	  have	  much	  lower	  rates.75,76,174	  With	  the	  
advent	  of	  sensitive	  molecular	  diagnostic	  tests	  that	  can	  be	  performed	  on	  nasopharyngeal	  aspirates	  
specimens	  that	  may	  be	  safely	  obtained	  in	  even	  hypoxic	  patients,	  the	  true	  burden	  of	  PCP	  in	  acute	  CAP	  
cohorts	  should	  be	  definitively	  established.120,175	  Further	  aetiological	  studies	  to	  define	  the	  burden	  of	  
atypical	  bacterial	  infection	  (i.e.	  Legionella	  spp.,	  Mycoplasma	  pneumoniae,	  Chlamydophila	  spp.)	  and	  
hence	  the	  need	  for	  atypical	  antimicrobial	  cover	  in	  empirical	  CAP	  therapy	  should	  also	  be	  undertaken.	  
With	  improved	  molecular-­‐based	  diagnostics,	  increasing	  proportions	  of	  patients	  are	  recognised	  to	  
have	  infection	  with	  respiratory	  viruses.63	  Their	  relevance	  to	  the	  aetiology	  of	  CAP,	  both	  as	  primary	  
cause	  and	  co-­‐pathogen	  with	  other	  organisms,	  should	  be	  investigated.	  
Few	  centres	  are	  able	  to	  offer	  diagnostic	  microbiology	  services,	  but	  there	  is	  ample	  evidence	  from	  
those	  that	  do	  that	  antimicrobial	  resistance	  is	  a	  key	  issue	  52,139,176.	  Surveillance	  studies	  are	  warranted	  
to	  determine	  resistance	  patterns,	  and	  to	  direct	  national	  antibiotic	  recommendations.	  
Early	  presentation	  and	  pre-­‐hospital	  care	  
Maximising	  recognition	  of	  illness	  at	  the	  individual	  level	  is	  the	  key	  to	  all	  healthcare	  delivery.	  For	  
children	  with	  pneumonia,	  guardian	  awareness	  of	  the	  features	  of	  illness	  is	  low.177	  However,	  long-­‐
established	  community	  level	  interventions,	  such	  as	  Integrated	  Management	  of	  Childhood	  Illness	  
(IMCI),	  enhance	  many	  aspects	  of	  pre-­‐hospital	  treatment	  and	  probably	  reduce	  mortality	  from	  acute	  
illness.178,179	  
In	  adult	  pneumonia,	  care	  seeking	  is	  geographically	  variable,	  and	  within	  one	  active	  surveillance	  
programme	  in	  rural	  Thailand,	  adults	  were	  reported	  to	  have	  lower	  rates	  of	  hospital	  attendance	  than	  
children.180	  The	  IMAI	  guidelines	  described	  above	  are	  increasingly	  forming	  the	  basis	  for	  primary	  care	  
delivery	  in	  resource-­‐limited	  settings,	  although	  evidence	  of	  efficacy	  is	  mostly	  unpublished.181	  IMAI,	  and	  
other	  national	  programmes	  for	  triage	  should	  be	  evaluated	  for	  their	  protocols	  to	  diagnose	  pneumonia,	  
and	  to	  identify	  those	  patients	  who	  need	  onward	  referral.	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Initial	  triage	  and	  treatment	  
Triage	  systems	  have	  been	  associated	  with	  decreased	  mortality	  in	  unselected	  children	  in	  sub-­‐Saharan	  
Africa.182	  Analogous	  systems	  for	  adults	  have	  been	  developed	  for	  low-­‐resource	  settings	  (e.g.	  Cape	  
Triage	  Score183),	  but	  even	  these	  presuppose	  significant	  medical	  knowledge.	  Simpler,	  perhaps	  non-­‐
compound	  measures	  of	  physiological	  derangement	  might	  be	  effective.	  The	  benefit	  of	  formalising	  
systems	  for	  patient	  flow,	  and	  prioritising	  the	  critically	  unwell	  should	  be	  the	  subject	  of	  further	  
implementation	  research.	  
Diagnostics	  
In	  skilled	  hands	  in	  the	  emergency	  department,	  thoracic	  ultrasound	  has	  a	  high	  accuracy	  for	  pneumonia	  
diagnosis	  (94%	  sensitivity	  and	  96%	  specificity).184	  Protocols	  for	  interpretation	  have	  not	  been	  validated	  
in	  resource-­‐limited	  settings,	  although	  ultrasound	  is	  becoming	  increasingly	  available	  and	  has	  been	  
shown	  to	  be	  useful	  in	  diagnosing	  ARDS	  in	  a	  Rwandan	  ICU	  study.185	  However,	  there	  are	  minimal	  data	  
on	  how	  chest	  ultrasound	  is	  being	  otherwise	  used.	  The	  potential	  benefits,	  including	  cost-­‐effectiveness	  
analysis	  of	  training	  should	  be	  undertaken.	  
Antimicrobial	  chemotherapy	  
The	  optimal	  antimicrobial	  regimen	  for	  the	  treatment	  of	  CAP	  in	  the	  high	  TB	  burden,	  HIV-­‐prevalent	  
settings	  that	  characterise	  much	  of	  sub-­‐Saharan	  Africa	  is	  unknown.	  As	  for	  CAP	  cohorts	  across	  the	  
world,	  selection	  of	  the	  initial	  regimen	  will	  almost	  always	  be	  empirical	  and	  there	  are	  several	  key	  
therapeutic	  questions.	  Firstly,	  given	  the	  high	  prevalence	  of	  TB	  in	  patients	  presenting	  clinically	  as	  acute	  
CAP,21,24,53,67	  there	  is	  potential	  for	  earlier	  TB	  treatment	  to	  improve	  outcomes.	  Strategies	  of	  empirical	  
TB	  treatment	  in	  groups	  at	  high	  risk	  of	  early	  mortality	  compared	  to	  the	  systematic	  use	  of	  near-­‐patient	  
diagnostics	  in	  pneumonia	  patients	  should	  be	  further	  evaluated.	  Secondly,	  for	  HIV-­‐positive	  patients	  
who	  are	  critically	  unwell,	  co-­‐initiation	  of	  PCP	  and	  antibacterial	  treatment	  in	  individuals	  should	  be	  
evaluated.	  New	  highly	  sensitive	  molecular	  tests	  discussed	  above	  could	  be	  trialled	  in	  tandem	  as	  a	  
“rule-­‐out”	  diagnostic	  and	  basis	  for	  de-­‐escalation	  of	  therapy.120,175	  Thirdly,	  the	  routine	  use	  of	  
macrolides	  for	  the	  treatment	  of	  severe	  CAP	  both	  for	  their	  activity	  against	  atypical	  bacteria	  and	  as	  dual	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therapy	  in	  pneumococcal	  pneumonia	  should	  be	  evaluated.	  The	  impact	  of	  any	  antimicrobial	  
intervention	  on	  rates	  of	  antimicrobial	  resistance	  should	  be	  closely	  monitored.	  	  
Adjuvant	  treatment	  
Fluids	  
Clinical	  measurement	  of	  fluid	  balance	  in	  critical	  care	  settings	  is	  subjective	  and	  difficult.146	  Consensus	  
guidelines	  on	  sepsis	  have	  been	  limited	  by	  a	  lack	  of	  objective	  definition	  of	  “adequate	  fluid	  
resuscitation.”	  Careful	  analysis	  of	  cardiovascular	  and	  respiratory	  outcomes	  of	  fluid	  resuscitation	  
should	  be	  undertaken.	  In	  the	  light	  of	  FEAST,147	  an	  analogous	  trial	  of	  conservative	  vs.	  bolus	  fluid	  
therapy	  in	  adults	  where	  there	  are	  no	  intensive	  care	  unit	  (ICU)	  facilities	  may	  be	  warranted.	  	  
Oxygen	  
Pragmatic	  recommendations	  from	  the	  WHO	  to	  use	  oxygen	  concentrators	  are	  based	  on	  the	  cost	  
benefit	  over	  the	  most	  available	  alternative	  –	  cylinders.186	  Step-­‐wedge	  interventions	  of	  oxygen	  
concentrators	  to	  healthcare	  centre	  who	  currently	  have	  insufficient	  oxygen	  capacity	  would	  be	  very	  
welcome.	  These	  could	  incorporate	  other	  health	  systems	  improvements,	  and	  could	  directly	  inform	  
policy.	  
Non-­‐invasive	  ventilation	  
Non-­‐invasive	  ventilation	  (NIV)	  has	  no	  established	  mortality	  benefit	  in	  CAP	  in	  any	  setting.187	  However,	  
endpoints	  in	  these	  trials	  are	  determined	  in	  the	  contexts	  of	  functioning	  ICU	  (with	  intubation	  as	  a	  
“treatment	  failure”).	  Where	  IPPV	  is	  not	  available,	  NIV	  might	  find	  a	  niche,	  but	  the	  authors	  are	  not	  
aware	  of	  any	  centres	  providing	  this.	  
Follow-­‐up	  
Little	  is	  known	  of	  longer-­‐term	  outcomes	  following	  CAP	  in	  resource-­‐limited	  settings,	  or	  if	  the	  adverse	  
cardiovascular	  outcomes	  seen	  in	  Western	  cohorts	  are	  applicable:	  this	  should	  be	  examined	  given	  the	  
higher	  rates	  of	  cardiovascular	  disease	  in	  HIV.188,189	  
Conclusion	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Community	  acquired	  pneumonia	  in	  sub-­‐Saharan	  Africa	  has	  strong	  similarities	  in	  disease	  aetiology	  and	  
treatment	  to	  high-­‐income	  countries.	  This	  review	  has	  highlighted	  areas	  of	  divergence,	  including	  high	  
rates	  of	  immunocompromised,	  low	  rates	  of	  clinical	  and	  laboratory	  support	  for	  patient	  management,	  
investigation,	  and	  an	  absence	  of	  region-­‐specific	  information	  on	  aetiology	  and	  the	  optimal	  treatment	  
regime.	  International	  guidelines,	  such	  as	  IMAI,	  have	  been	  consciously	  devised	  with	  these	  difficulties	  in	  
mind.	  The	  knowledge	  gaps	  offer	  potential	  for	  major	  gains	  in	  mortality,	  and	  research	  should	  be	  
tailored	  to	  regional	  populations	  and	  regional	  resource	  limitations.	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